IN VIVO INVESTIGATION OF THE EFFECTS OF THE C-4 COMPOSITION ON THE FUNCTIONAL STATE OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS
In the development of pharmacological agents and their introduction into clinical practice, it is essential to comprehensively
evaluate not only their primary therapeutic activity but also their effects on the vital systems of the body, including the central
nervous system. In the present experimental study, the effects of the C-4 composition on the functional state of the central nervous
system were investigated at a therapeutic dose of 10 mg/kg and at a dose of 20 mg/kg, which was twice the therapeutic dose. The
obtained results showed that the combined administration of the C-4 composition with sedative agents did not cause pronounced
adverse effects. At the same time, the composition was found to exhibit antagonistic properties against the pharmacological effects
of certain hypnotic agents, particularly chloral hydrate. These findings are of considerable scientific and practical importance for
evaluating the effects of the C-4 composition on the central nervous system and determining its safety profile.
1. European Directive 2010/63/EU on the protection of animals used for scientific purposes. September 22, 2010. Official
Journal of the European Union, L 276/33- L276/79
2. Руководство по проведению доклинических исследований лекарственных средств. Часть первая /Под ред. А.Н.
Миронова. М.: Гриф и К, 2012. - 944 с.
3. OECD (2001) Guideline for testing of chemicals. Acute Oral Toxicity – Fixed Dose Procedure No 420.
4. IСH harmonised tripartite guideline guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for
human use. International conference on harmonisation of technical requirements for registration of pharmaceuticals for
human use. S2(r1). Current Step 4 version dated 9 November 2011.
5. ГОСТ Р 57146-2016 Лекарственные средства. для медицинского применения. Изучение канцерогенности
лекарственных средств и вспомогательных веществ (ЮН S1А:1995, Guideline on need for carcinogenicity of
pharmaceuticals, MOD) (S1B:1997, Testing for carcinogenicity of pharmaceuticals, MOD) (S1C(R2):2008, Dose selection
for carcinogenicity studies of pharmaceuticals, MOD.
Copyright (c) 2026 «ACTA NUUz»

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




.jpg)

1.png)




